COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

TR1801-ADC in Patients With Tumors That Express c-Met

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03859752
Recruitment Status : Recruiting
First Posted : March 1, 2019
Last Update Posted : September 11, 2020
Open Innovation Partners
Information provided by (Responsible Party):
Tanabe Research Laboratories USA Inc

Brief Summary:
First-in-human, Phase 1 study to assess safety, tolerability, and pharmacokinetics of TR1801-ADC in patients with select solid tumors that express c-Met.

Condition or disease Intervention/treatment Phase
Unspecified Adult Solid Tumor, Protocol Specific Biological: TR1801-ADC Phase 1

Detailed Description:
First-in-human, Phase 1, multiple dose-dose escalation study designed to determine safety, tolerability, maximum tolerated dose, and recommended phase 2 dose of TR1801-ADC in patients with select solid tumors that express c-Met. This study will also assess pharmacokinetics (PK), anti-tumor activity, and correlation between clinical outcomes (safety, anti-tumor activity, and PK) and c-Met expression.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open label, multiple dose, dose-escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met
Actual Study Start Date : August 14, 2019
Estimated Primary Completion Date : March 1, 2023
Estimated Study Completion Date : March 1, 2023

Arm Intervention/treatment
Experimental: TR1801-ADC
Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
Biological: TR1801-ADC
Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin

Primary Outcome Measures :
  1. Characterize safety of TR1801-ADC in patients with advanced solid tumor malignancies which express c-Met [ Time Frame: 2 years ]
    Number of participants with treatment-related adverse events

  2. Establish maximum tolerated dose [ Time Frame: 1.5 years ]
    Number of participants with protocol-defined dose-limiting toxicity

Secondary Outcome Measures :
  1. Evaluate pharmacokinetics of TR1801-ADC [ Time Frame: 2 years ]
    Analyze blood plasma concentrations

  2. Immunogenicity [ Time Frame: 2 years ]
    Assess anti-drug antibodies of TR1801-ADC

  3. Evaluate clinical activity of TR1801-ADC [ Time Frame: 3 years ]
    Assess objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST V1.1)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Compliance with all study procedures and visits to the clinical research site
  • Locally advanced or metastatic disease that is not amenable to definitive therapy
  • Histologically confirmed diagnosis of a solid tumor which expresses c-Met
  • Must have progressed or have been intolerant to all available therapies known to confer clinical benefit appropriate for the patient's tumor type
  • Measurable baseline disease as defined by RECIST Version 1.1
  • ECOG Performance Status 0-1
  • Body weight within 40 and 150 kg
  • Clinical laboratory values with the limits as defined by the protocol
  • Not pregnant or breast feeding
  • Males and women of child-bearing potential must agree to use an effective method of contraception

Exclusion Criteria:

  • Any disease or condition that may be considered to pose an increased risk from study treatment or the ability of the patient to participate and comply with study procedures
  • Treatment with anti-cancer therapy (including cytotoxic chemotherapy, major surgery, radiation, biologic and investigational agents) within 21 days before first dose of study treatment
  • Brain metastases that has not stabilized for at least 28 days after therapy and who have discontinued steroids for <2 weeks
  • Unresolved adverse events >= Grade 2 from prior anticancer therapies
  • Acute myocardial infarction, cerebral ischemic infarct, or other arterial thrombosis within 6 months of screening for this study.
  • Uncontrolled hypertension, unstable angina, or NYHA Class III/IV heart failure
  • Untreated or uncontrolled bacterial, viral or fungal infection
  • HIV infection or active infection with hepatitis B or C
  • Prior treatment with a c-Met targeted agent
  • Prior hypersensitivity reaction to treatment with another monoclonal antibody
  • QTcF >=470 ms
  • Administration of a live, attenuated vaccine within 28 days before the first dose of study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03859752

Layout table for location contacts
Contact: Jasmine Hill (438) 806-3845
Contact: Crystal Jenkins (910) 240-3104

Layout table for location information
United States, California
University of Southern California Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Lorraine Martinez, LVN   
Principal Investigator: Jacob Thomas, MD         
Hoag Memorial Hospital Presbyterian Recruiting
Newport Beach, California, United States, 92663
Contact: Leila Andres, MS    949-764-8092   
Principal Investigator: Jacob Thomas, MD         
United States, Colorado
University of Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Sheri Neu    720-848-0691   
Principal Investigator: Wells Messersmith, MD         
United States, Maryland
John Hopkins - Sidney Kimmel Comprehensive Cancer Center Recruiting
Baltimore, Maryland, United States, 21287
Contact: Jenn Hale    410-502-5140   
Principal Investigator: Kristen Marrone, MD         
United States, Washington
University of Washington / Seattle Cancer Care Recruiting
Seattle, Washington, United States, 98109
Contact: Hannah Lee    206-606-7051   
Principal Investigator: Kit Wong, MD         
Sponsors and Collaborators
Tanabe Research Laboratories USA Inc
Open Innovation Partners
Layout table for investigator information
Study Director: Ken Carlson, MD Tanabe Research Laboratories
Layout table for additonal information
Responsible Party: Tanabe Research Laboratories USA Inc Identifier: NCT03859752    
Other Study ID Numbers: TR1801-CL-01
First Posted: March 1, 2019    Key Record Dates
Last Update Posted: September 11, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tanabe Research Laboratories USA Inc:
antibody-drug conjugate
solid tumors
Phase 1
Additional relevant MeSH terms:
Layout table for MeSH terms